Literature DB >> 15451399

GABA transporters as drug targets for modulation of GABAergic activity.

Arne Schousboe1, Alan Sarup, Orla M Larsson, H Steve White.   

Abstract

The identification and subsequent development of the GABA transport inhibitor tiagabine has confirmed the important role that GABA transporters play in the control of CNS excitability. Tiagabine was later demonstrated to be a selective inhibitor of the GABA transporter GAT1. Although selective for GAT1, tiagabine lacks cell type selectivity and is an equipotent inhibitor of neuronal and glial GAT1. To date, four GABA transporters have been cloned, i.e., GAT1-4. The finding that some of these display differential cellular and regional expression patterns suggests that drugs targeting GABA transporters other than GAT1 might offer some therapeutic advantage over GAT1 selective inhibitors. Furthermore, it is particularly interesting that several recently defined GABA transport inhibitors have been demonstrated to display a preferential selectivity for the astrocytic GAT1 transporter. That cellular heterogeneity of GAT1 plays a role in the control of CNS function is confirmed by the demonstration that inhibition of astrocytic GABA uptake is highly correlated to anticonvulsant activity. At the present time, a functional role for the other GABA transporters is less well defined. However, recent findings have suggested a role for the mouse GAT2 (homologous to the human betaine transporter) in the control of seizure activity. In these studies, the non-selective GAT1 and mouse GAT2 transport inhibitor EF1502 (N-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-hydroxy-4-(methylamino)-4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol) was found to exert a synergistic anticonvulsant action when tested in combination with the GAT1 selective inhibitors tiagabine and LU-32-176B (N-[4,4-bis(4-fluorophenyl)-butyl]-3-hydroxy-4-amino-4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol). Additional studies will be required to define a role for the other GABA transporters and to further identify the functional importance of their demonstrated cellular and regional heterogeneity. A summary of these and other issues are discussed in this brief review.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15451399     DOI: 10.1016/j.bcp.2004.06.041

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  21 in total

1.  Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain.

Authors:  Amanda Ford; Annie Castonguay; Martin Cottet; Joshua W Little; Zhoumou Chen; Ashley M Symons-Liguori; Timothy Doyle; Terrance M Egan; Todd W Vanderah; Yves De Koninck; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

Review 2.  The micro-architecture of the cerebral cortex: functional neuroimaging models and metabolism.

Authors:  Jorge J Riera; Arne Schousboe; Helle S Waagepetersen; Clare Howarth; Fahmeed Hyder
Journal:  Neuroimage       Date:  2008-01-11       Impact factor: 6.556

3.  Tiagabine treatment in kainic acid induced cerebellar lesion of dystonia rat model.

Authors:  Tsui-Chin Wang; Sukonthar Ngampramuan; Naiphinich Kotchabhakdi
Journal:  EXCLI J       Date:  2016-11-17       Impact factor: 4.068

4.  The Concise Guide to PHARMACOLOGY 2013/14: transporters.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Conformationally Restricted GABA with Bicyclo[3.1.0]hexane Backbone as the First Highly Selective BGT-1 Inhibitor.

Authors:  Takaaki Kobayashi; Akihiro Suemasa; Arisa Igawa; Soichiro Ide; Hayato Fukuda; Hiroshi Abe; Mitsuhiro Arisawa; Masabumi Minami; Satoshi Shuto
Journal:  ACS Med Chem Lett       Date:  2014-06-16       Impact factor: 4.345

6.  Effect of hyperosmotic conditions on the expression of the betaine-GABA-transporter (BGT-1) in cultured mouse astrocytes.

Authors:  Mads Olsen; Alan Sarup; Orla M Larsson; Arne Schousboe
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

7.  Distinct gene expression profiles directed by the isoforms of the transcription factor neuron-restrictive silencer factor in human SK-N-AS neuroblastoma cells.

Authors:  Stuart G Gillies; Kate Haddley; Sylvia A Vasiliou; Gregory M Jacobson; Bengt von Mentzer; Vivien J Bubb; John P Quinn
Journal:  J Mol Neurosci       Date:  2010-07-23       Impact factor: 3.444

Review 8.  GABA and central neuropathic pain following spinal cord injury.

Authors:  Young S Gwak; Claire E Hulsebosch
Journal:  Neuropharmacology       Date:  2011-01-07       Impact factor: 5.250

9.  Effects of cocaine and withdrawal on the mouse nucleus accumbens transcriptome.

Authors:  J E Eipper-Mains; D D Kiraly; M O Duff; M J Horowitz; C J McManus; B A Eipper; B R Graveley; R E Mains
Journal:  Genes Brain Behav       Date:  2012-11-27       Impact factor: 3.449

Review 10.  GABA effects during neuronal differentiation of stem cells.

Authors:  Patricia Salazar; Marco A Velasco-Velázquez; Iván Velasco
Journal:  Neurochem Res       Date:  2008-03-21       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.